Multidisciplinary approach to the treatment of locally and regionally advanced non‐small cell lung cancer: University of Miami experience

K. S. Sridhar, R. J. Thurer, A. M. Markoe, H. T. Chatoor, G. Fountzilas, W. J. Raub, N. Savaraj, E. J. Beattie

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

An intensive multimodality therapy protocol incorporating neoadjuvant chemotherapy was initiated in July 1985 for patients with either borderline resectable or unresectable non‐small cell carcinoma of the lung. Thirty‐five patients, 21 men and 14 women were entered till March 1991. The median age was 58 years (27–74). Histology was squamous in 15, adenocarcinoma in 11, large cell in 6, and adenosqua‐mous carcinoma in 3. Initial stages were IIIA in 19 patients, IIIB in 14 and II in 2. All patients tolerated preoperative chemotherapy with 5‐FU, etoposide and cisplatin (FED). The response to chemotherapy was complete response in 2 (6%), and partial response in 22 (63%). Thirty‐two patients underwent surgery. 26 patients were rendered disease free including two found disease free at surgery. Fifteen underwent pneumonectomy, 14 lobectomy and 3 biopsy only. Interstitial radiation therapy was used in 7 patients. The median survival of all patients was 19 months, those who underwent incomplete surgical resection was 12 months and patients rendered disease free at operation 21 months. Thirteen patients are alive and free of disease, including 6 patients alive longer than 5 years. Only patients who responded to chemotherapy and also had compete resection survived more than 2 years. Aggressive neoadjuvant therapy with FED, followed by resection, brachytherapy, postoperative radiation therapy, and adjuvant chemotherapy can be safely accomplished with encouraging survival in Stage III patients.

Original languageEnglish (US)
Pages (from-to)114-119
Number of pages6
JournalSeminars in Surgical Oncology
Volume9
Issue number2
DOIs
StatePublished - Jan 1 1993

    Fingerprint

Keywords

  • FED
  • chemotherapy
  • neoadjuvant therapy
  • non‐small cell lung cancer

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this